Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis [0.03%]
中国严重非抑制性甲型血友病患者恩利珠单抗预防治疗的终身成本效用分析：马尔可夫模型分析
Han Bao,Christian Bührer,Ziyi Lin et al.
Han Bao et al.
Aim: As emicizumab shares no sequence homology with factor VIII (FVIII), in patients with haemophilia A, haemostasis can be restored irrespective of the presence of FVIII inhibitors. Emicizumab, therefore, substantially i...
Hemophilia Severity and Its Association With Mental Health and Health-Related Quality of Life-Results From a Cross-Sectional Multicenter Study [0.03%]
血友病的严重程度及其与心理健康和生活质量的关系——一项基于多中心横断面研究的结果
Francesca Schmitt,Laura Maier,Stefan Lerch et al.
Francesca Schmitt et al.
Background: Limited existing research on mental health and health-related quality of life (HRQoL) in people with hemophilia (PwH) suggests these patients still may have poor mental health despite treatment advances signif...
Enhancing the Evidence for Care in Underserved Bleeding Disorders Communities [0.03%]
增强罕见出血障碍社区的护理证据力
Johnny Mahlangu
Johnny Mahlangu
Background: Major advances in haemophilia care have not translated equitably across all populations. Individuals with rare bleeding disorders (RBDs), people living in low- and lower-middle-income countries (LMICs) and wom...
Key Findings From the World Federation of Haemophilia National Member Organization Survey on Women and Girls With Bleeding Disorders [0.03%]
世界血友病 federation 国家成员组织关于女性和出血障碍女孩调查的主要发现摘要
Donna Coffin,Yannick Collé,Roshni Kulkarni et al.
Donna Coffin et al.
Introduction: Women and girls with bleeding disorders (WGBD) face challenges in accessing timely and specialized care. There is a need for comprehensive data, particularly regarding care and clinical management, to inform...
Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments [0.03%]
不同预防治疗方案对重度血友病成人患者骨骼健康的影响
Ting-Wei Lyu,Wei-Yih Chiu,Ting Sun et al.
Ting-Wei Lyu et al.
Introduction: Haemophilia, an X-linked disorder, is linked to reduced bone mineral density (BMD). Emicizumab, a factor VIII (FVIII) mimetic, provides a model to study the role of FVIII in bone health. ...
Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry-Based Matched Cohort Study [0.03%]
基于登记数据的匹配队列研究评估血友病患者骨折负担
Federico Germini,Arun Keepanasseril,Quazi Ibrahim et al.
Federico Germini et al.
Background: Bone diseases, such as low bone mineral density and osteoporosis is an emerging concern in people with haemophilia (PWH). As a consequence, PWH might experience fractures more frequently than the general popul...
Bridging the Gap: Efficacy of Low-Dose Emicizumab in Haemophilia A With or Without Inhibitors [0.03%]
低剂量艾米珠单抗治疗甲型血友病(有或无抑制物)的疗效
Gaurav Datta,Shailendra Prasad Verma,Swasti Sinha et al.
Gaurav Datta et al.
Introduction: Emicizumab has proven to be a turning point in the management of patients with Haemophilia A (HA). In resource-limited settings, data on low-dose emicizumab prophylaxis (LDEP) in HA patients are emerging. ...
Managing Acute Coronary Syndrome and Surgical Revascularization in a Patient With Severe Haemophilia A on Emicizumab: Lessons Learned From a Clinical Case [0.03%]
艾美赛珠单抗治疗A型血友病合并急性冠脉综合征及外科手术的经验教训
Paige Muir,Rohan Sanjanwala,Angelina Marinkovic et al.
Paige Muir et al.